Cyclophosphamide for multiple sclerosis

Mantia, L. La; Milanese, C.; Mascoli, Nerina; D'Amico, Roberto; Weinstock‐Guttman, Bianca

doi:10.1002/14651858.cd002819.pub2

Cited by 46 publications

(23 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to a lack of evidence from randomized, controlled clinical trials, the use of cyclophosphamide in MS and CIDP is not properly established [25,47].…”

Section: Established Intravenous Immunosuppressive Drugs: Mitoxantronmentioning

confidence: 99%

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Melzer

Meuth

2014

Clin Exp Immunol

View full text Add to dashboard Cite

OTHER ARTICLES PUBLISHED IN THIS SERIESParaneoplastic neurological syndromes. Clinical and Experimental Immunology 2014, 175: 336-48. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical and Experimental Immunology 2014, 175: 349-58. Monoclonal antibodies in treatment of multiple sclerosis. Clinical and Experimental Immunology 2014, 175: 373-84 SummaryMultiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) represent chronic, autoimmune demyelinating disorders of the central and peripheral nervous system. Although both disorders share some fundamental pathogenic elements, treatments do not provide uniform effects across both disorders. We aim at providing an overview of current and future disease-modifying strategies in these disorders to demonstrate communalities and distinctions.

show abstract

“…Due to a lack of evidence from randomized, controlled clinical trials, the use of cyclophosphamide in MS and CIDP is not properly established [25,47].…”

Section: Established Intravenous Immunosuppressive Drugs: Mitoxantronmentioning

confidence: 99%

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Melzer

Meuth

2014

Clin Exp Immunol

View full text Add to dashboard Cite

show abstract

“…Their actions seem to reduce inflammatory activity in the central nervous system, as confirmed by MRI studies. However, their safety profiles are characterized by several adverse effects, such as leukopenia with increased risk of infection, nausea and alopecia for cyclophosphamide therapy, 26 and a possible long-term risk of malignant growth related to the duration of treatment and cumulative dose for azathioprine therapy.…”

Section: Box 1: Evidence Used In This Reviewmentioning

confidence: 99%

Drug therapy for multiple sclerosis

Rovaris

Mantia

2014

CMAJ

Self Cite

View full text Add to dashboard Cite

Review CMAJ• Currently available medications for the treatment of relapsingremitting MS are heterogeneous in terms of efficacy (higher for natalizumab and fingolimod) and safety profile (better for glatiramer acetate and interferon-β).• Disease-modifying treatments should be started early in patients with relapsing-remitting MS.• Multiple sclerosis relapses should be treated with short courses of steroids to favour faster clinical recovery.• The choice of medication in patients naive to treatment should be made on an individual basis, with consideration for both medical indications and patient expectations.• A shift to natalizumab or fingolimod treatment is recommended if there is a poor response to glatiramer acetate or interferon-β.

show abstract

“…Mitoxantrone is approved in the majority of the countries represented in the Forum and has been used as an induction treatment for very aggressive MS (non-responsive, rapidly progressive, secondary progressive and very active MS), prior to treatment with first-line drugs 25 . In these cases, this drug reduces relapse rates and the disability assessed by the EDSS score, thereby delaying disease progression.…”

Section: Use Of Other Drugs In Special Situationsmentioning

confidence: 99%

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents

Finkelsztejn

Gabbai

Fragoso

et al. 2012

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and NorthAmerican algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. Methods:The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed. Results: A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also discussed. Conclusions: The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to our region directly from purely European and North-American guidelines for treatment.Key words: multiple sclerosis, treatment, Latin America. RESUMOObjetivo: Estima-se que haja aproximadamente 50.000 pessoas com a forma remitente-recorrente da esclerose múltipla na América Latina. Os algoritmos de tratamento norte-americanos e europeus não levam em consideração nossas peculiaridades regionais, nem a dificuldade no acesso ao tratamento por parte dos pacientes. Métodos: O Fórum Latino-americano de Esclerose Múltipla é um grupo de especialistas independente e suprainstitucional, que avaliou as mais recentes evidências científicas sobre a eficácia e a segurança das drogas modificadoras do curso da doença. Foram avaliados também o acesso ao tratamento e os programas de farmacovigilância de cada

show abstract

Cyclophosphamide for multiple sclerosis

Cited by 46 publications

References 66 publications

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Drug therapy for multiple sclerosis

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents

Contact Info

Product

Resources

About